239 related articles for article (PubMed ID: 32180097)
1. Anticancer Actions of Azurin and Its Derived Peptide p28.
Huang F; Shu Q; Qin Z; Tian J; Su Z; Huang Y; Gao M
Protein J; 2020 Apr; 39(2):182-189. PubMed ID: 32180097
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
3. p28 Bacterial Peptide, as an Anticancer Agent.
Yaghoubi A; Khazaei M; Avan A; Hasanian SM; Cho WC; Soleimanpour S
Front Oncol; 2020; 10():1303. PubMed ID: 32850408
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of the anticancer p28 peptide in biomimetic medium.
Cantini F; Gianni' P; Savarin P; Bizzarri AR; Sette M
J Pept Sci; 2021 Nov; 27(11):e3357. PubMed ID: 34151482
[TBL] [Abstract][Full Text] [Related]
6. Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.
Gao M; Zhou J; Su Z; Huang Y
Protein Sci; 2017 Dec; 26(12):2334-2341. PubMed ID: 28960574
[TBL] [Abstract][Full Text] [Related]
7. Noncationic peptides obtained from azurin preferentially enter cancer cells.
Taylor BN; Mehta RR; Yamada T; Lekmine F; Christov K; Chakrabarty AM; Green A; Bratescu L; Shilkaitis A; Beattie CW; Das Gupta TK
Cancer Res; 2009 Jan; 69(2):537-46. PubMed ID: 19147567
[TBL] [Abstract][Full Text] [Related]
8. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.
Yamada T; Mehta RR; Lekmine F; Christov K; King ML; Majumdar D; Shilkaitis A; Green A; Bratescu L; Beattie CW; Das Gupta TK
Mol Cancer Ther; 2009 Oct; 8(10):2947-58. PubMed ID: 19808975
[TBL] [Abstract][Full Text] [Related]
9. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
[TBL] [Abstract][Full Text] [Related]
10. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
Santini S; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
[TBL] [Abstract][Full Text] [Related]
11. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.
Ramachandran S; Mandal M
Biomed Pharmacother; 2011 Oct; 65(7):461-6. PubMed ID: 22000294
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination.
Hu J; Jiang W; Zuo J; Shi D; Chen X; Yang X; Zhang W; Ma L; Liu Z; Xing Q
Commun Biol; 2023 Jan; 6(1):59. PubMed ID: 36650277
[TBL] [Abstract][Full Text] [Related]
14. Microbial Azurin Immobilized on Nano-Chitosan as Anticancer and Antibacterial Agent Against Gastrointestinal Cancers and Related Bacteria.
Al-Hazmi NE; Naguib DM
J Gastrointest Cancer; 2022 Sep; 53(3):537-542. PubMed ID: 34159520
[TBL] [Abstract][Full Text] [Related]
15. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
Warso MA; Richards JM; Mehta D; Christov K; Schaeffer C; Rae Bressler L; Yamada T; Majumdar D; Kennedy SA; Beattie CW; Das Gupta TK
Br J Cancer; 2013 Mar; 108(5):1061-70. PubMed ID: 23449360
[TBL] [Abstract][Full Text] [Related]
16. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53.
Nguyen C; Nguyen VD
Biomed Res Int; 2016; 2016():8490482. PubMed ID: 27239476
[TBL] [Abstract][Full Text] [Related]
18. p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer.
Garizo AR; Castro F; Martins C; Almeida A; Dias TP; Fernardes F; Barrias CC; Bernardes N; Fialho AM; Sarmento B
J Control Release; 2021 Sep; 337():329-342. PubMed ID: 34311024
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activity of
Yaghoubi A; Movaqar A; Asgharzadeh F; Derakhshan M; Ghazvini K; Hasanian SM; Avan A; Mostafapour A; Khazaei M; Soleimanpour S
Iran J Basic Med Sci; 2023; 26(7):768-776. PubMed ID: 37396945
[TBL] [Abstract][Full Text] [Related]
20. Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53.
Punj V; Das Gupta TK; Chakrabarty AM
Biochem Biophys Res Commun; 2003 Dec; 312(1):109-14. PubMed ID: 14630027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
